Diabetes, Metabolic Syndrome and Obesity (Aug 2020)
Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range
Abstract
Amal Hasan,1 Waleed Aldhahi2,3 1Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait; 2Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 3Department of Medicine, Mubarak Al-Kabeer Hospital, Kuwait City, KuwaitCorrespondence: Amal Hasan Email [email protected]: Cardiovascular disease can be detected in individuals with prediabetes. The purpose of this study was to determine whether soluble suppression of tumorigenicity 2 (sST2), which is elevated in cardiovascular disease and/or type 2 diabetes, is correlated with glycated haemoglobin in individuals with glycemia in the normal/prediabetes range.Patients and Methods: The anthropometric, biochemical and metabolic parameters were measured in 30 adults, and the plasma levels of sST2 were quantified.Results: sST2 was directly correlated with glycated hemoglobin in individuals with glycemia in the normal/prediabetes range. Participants who were at the higher end of glycated hemoglobin (5.8– 6.4%) had significantly higher sST2 compared to those at the lower end (≤ 5.5%). Moreover, sST2 was directly correlated with homeostatic model assessment of insulin resistance (HOMA-IR), alkaline phosphatase, and waist circumference. However, the correlation between sST2 and HOMA-IR or waist circumference was lost after adjusting for age, gender or body mass index.Conclusion: Circulating sST2 may be used to establish a cut-off value for cardiometabolic risk/disease in individuals with glycemia in the normal/prediabetes range.Keywords: glycated hemoglobin, prediabetes, soluble suppression of tumorigenicity 2
